One study indicates that elevated TIM-3 expression on PRAD cells predicts shorter recurrence-free survival and progression-free survival in chemotherapy- and radiotherapy-naïve PRAD patients [80]. The gene discussed is HAVCR2; the disease is prostate adenocarcinoma.